Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810557 | 0.95 | KDM4E (0.41) | KDM4EKMT2ASLC6A4ALDH1A1MAPT | |
| SCHEMBL15197151 | 0.87 | KDM4E (0.38) | KDM4EKMT2ASLC6A4ALDH1A1MAPT | |
| SCHEMBL21175823 | 0.81 | HPGD (0.46) | KDM4EKMT2ASLC6A4ALDH1A1NPC1 | |
| SCHEMBL2934176 | 0.81 | KDM4E (0.48) | KDM4EKMT2AALDH1A1MAPTLMNA | |
| SCHEMBL3469320 | 0.80 | KDM4E (0.37) | KDM4EKMT2ASLC6A4ALDH1A1MAPT | |
| SCHEMBL2807581 | 0.80 | KMT2A (0.33) | KDM4EKMT2ASLC6A4ALDH1A1MAPT | |
| SCHEMBL21985350 | 0.78 | SKP2 (0.43) | KMT2AALDH1A1MAPTNPC1LMNA | |
| SCHEMBL17124808 | 0.78 | TAAR1 (0.49) | KDM4EKMT2AALDH1A1MAPTLMNA | |
| SCHEMBL2812775 | 0.77 | NAMPT (0.34) | KMT2AMAPTTAAR1 | |
| SCHEMBL6849954 | 0.77 | ALDH1A1 (0.35) | KDM4EKMT2AALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| EP-1689712-B1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| EP-1689712-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | KDM4E 3162/4885KMT2A 4420/4885SLC6A4 666/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | KDM4E 3091/4885KMT2A 4374/4885SLC6A4 797/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | KDM4E 3091/4885KMT2A 4374/4885SLC6A4 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.